Biologic Therapy in Pediatric JIA Uveitis

• Status: Active, not recruiting
• Trial end date: 2024-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Juvenile Idiopathic Arthritis (JIA) remains the most common systemic disorder associated with pediatric uveitis. Studies estimate that 28-67% of patients with JIA-associated uveitis develop ocular complications, with 12% developing poor visual outcome. The only means of improving long term effects of uveitis, is early and aggressive anti-inflammatory treatment, including biologics.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kasr El Aini Hospital
• Treatments: Adalimumab

Criteria

Inclusion Criteria:

• Diagnosed JIA according to rheumatological criteria with ocular affection

• Any type of arthritis (oligoarticular, polyarticular, systemic onset, ocular JIA)

• ANA positive or negative

• Uncontrolled uveitis or frequent relapses

Exclusion Criteria:

• 1.Patients without definitive diagnosis as JIA 2. JIA patients on biologics without ocular affection (for systemic control) or with uveitis controlled without the use of biologics 3.Patients without adequate duration for follow-up (less than 3 months) or lost follow up data 4.Patients without available data prior to the start biologics (to compare control of the uveitis)